TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2917114

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 10 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 5 micrograms kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glycopyrronium 5 micrograms kg‐1 and 10 micrograms kg‐1
Number of subjects: 60
Study: 162675

Group type: EXPERIMENTAL
Intervention: Isoxsuprine 10 mg, acetaminophen 250 mg, caffeine 30 mg
Number of subjects: 80
Study: 31429790

Group type: EXPERIMENTAL
Intervention: Yi-Zhi-An-Shen granules (YZASG) administered three times a day for 16 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo administered three times a day for 16 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Yi-Zhi-An-Shen granules (YZASG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24673165

Group type: EXPERIMENTAL
Intervention: 40 mg of oral zinc sulphate tablets for 14 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 23840944

Group type: EXPERIMENTAL
Intervention: Participants with a social contact
Number of subjects: 92

Group type: COMPARATOR
Intervention: Participants without a social contact
Number of subjects: 92
Study: 21048508

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 64

Group type: COMPARATOR
Intervention: Latanoprost-timolol-fixed combination (LTFC)
Number of subjects: 64
Study: 19636660

Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neosaxitoxin (10 microg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neosaxitoxin (10 microg) plus Bupivacaine (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neosaxitoxin (10 microg) plus Epinephrine (1:100,000)
Number of subjects: 10
Study: 17869295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3047

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3047

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 3047

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 3047
Study: 15557853

Group type: EXPERIMENTAL
Intervention: 2x Galilean telescope
Number of subjects: 16

Group type: COMPARATOR
Intervention: Simple monocular tube
Number of subjects: 16
Study: 11595622

Group type: EXPERIMENTAL
Intervention: Endogenous estradiol (E2)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Endogenous estrone (E1)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Endogenous testosterone (T)
Number of subjects: 704
Study: 9216352

Group type: EXPERIMENTAL
Intervention: Combined medical and cognitive-behavioral treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 94
Study: 8439511

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 3087657

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 45

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate and Astemizole
Number of subjects: 45
Study: 31528769

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TA) injection
Number of subjects: 51

Group type: COMPARATOR
Intervention: Incision and curettage (I&C)
Number of subjects: 51
Study: 29040223

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg·d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26869286

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Local muscle vibration (LMV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 25445081

Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy (SET)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Exposure therapy alone
Number of subjects: 106

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 106
Study: 22704056

Group type: EXPERIMENTAL
Intervention: PRO-SELF Pain Control Program
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 179
Study: 20666949

Group type: EXPERIMENTAL
Intervention: Ablative curettage using a Thabet double‐bladed sharp curette
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overcurettage using Sims sharp curette
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ablative curettage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overcurettage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hysterectomy specimens
Number of subjects: 100
Study: 17872493

Group type: EXPERIMENTAL
Intervention: Mepolizumab 250 mg
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Mepolizumab 750 mg
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 16547376

Group type: EXPERIMENTAL
Intervention: Newborns of diabetic mothers (IDM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy newborns delivered at term (Control)
Number of subjects: 53
Study: 11835697

Group type: EXPERIMENTAL
Intervention: Eucor (generic simvastatin)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Zocor (original simvastatin)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both Eucor and Zocor
Number of subjects: 43
Study: 10201670

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask (ILM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Laryngeal Mask Airway (LMA)
Number of subjects: 20
Study: 7760780

Group type: EXPERIMENTAL
Intervention: Exposed group (residents near the plant)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Unexposed group (referents)
Number of subjects: 197
Study: 1706804

Group type: EXPERIMENTAL
Intervention: Apresoline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Slow-release hydralazine (SRH)
Number of subjects: 16
Study: 555600

Group type: EXPERIMENTAL
Intervention: Pirbuterol 15 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metaproterenol 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pirbuterol 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31466764

Group type: EXPERIMENTAL
Intervention: Exercise-heat acclimation (HA)
Number of subjects: 13
Study: 28216365

Group type: EXPERIMENTAL
Intervention: LiquoGuard automated device
Number of subjects: 152

Group type: COMPARATOR
Intervention: Traditional dripping chamber-based system
Number of subjects: 152
Study: 25914334

Group type: EXPERIMENTAL
Intervention: Trigonella foenum‐graecum seed extract (libifem) at a dose of 600 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24096616

Group type: EXPERIMENTAL
Intervention: Amlodipine/losartan 5/50 mg or 5/100 mg
Number of subjects: 99
Study: 21872978

Group type: EXPERIMENTAL
Intervention: Coiled-end swan neck catheter (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Straight-end swan neck catheter (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Coiled catheters (meta-analysis)
Number of subjects: 80
Study: 19723320

Group type: EXPERIMENTAL
Intervention: Nifedipine (intervention) for 48 hours
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (control) for 48 hours
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Nifedipine and Placebo (both groups)
Number of subjects: 220
Study: 16707943

Group type: EXPERIMENTAL
Intervention: Personal digital assistants (PDAs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Paper resources (Control)
Number of subjects: 36
Study: 15701215

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 11343482

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Oral contraceptive (OC)
Number of subjects: 1417
Study: 9390667

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) - 3 oral doses (14, 8, and 2 hours prior to testing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 7942524

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin (various dosages)
Number of subjects: 8245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study: 3392125

Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 60
Study: 29995739

Group type: EXPERIMENTAL
Intervention: Educational video on aneuploidy testing
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 92
Study: 26387039

Group type: EXPERIMENTAL
Intervention: Gefitinib monotherapy (250 mg/body) for 8 weeks followed by cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3‐dimensional conformal thoracic radiotherapy (2 Gy daily for 5 days a week to a total of 60 Gy)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3‐dimensional conformal thoracic radiotherapy (2 Gy daily for 5 days a week to a total of 60 Gy)
Number of subjects: 21
Study: 25311217

Group type: EXPERIMENTAL
Intervention: LHRHa plus AA
Number of subjects: 58

Group type: COMPARATOR
Intervention: LHRHa alone
Number of subjects: 58
Study: 23193534

Group type: EXPERIMENTAL
Intervention: BNO 1016
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19574099

Group type: EXPERIMENTAL
Intervention: Intervention group (n=17)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 38
Study: 18539624

Group type: EXPERIMENTAL
Intervention: Blastocyst biopsy followed by preimplantation genetic screening (PGS) for aneuploidy using 5-colour FISH
Number of subjects: 0
Study: 15317320

Group type: EXPERIMENTAL
Intervention: Benzylpenicilloyl-polylysine (5 mg/mL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: PrePen (5 mg/mL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Benzylpenicilloyl-polylysine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) for PrePen and benzylpenicilloyl-polylysine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cutaneous testing on penicillin-allergic individuals
Number of subjects: 11
Study: 11583635

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization
Number of subjects: 197

Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 197
Study: 9013058

Group type: EXPERIMENTAL
Intervention: four-pellet group (174 mg NET)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: five-pellet group (266.5 mg NET)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: four-pellet group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: five-pellet group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: four-pellet group and five-pellet group
Number of subjects: 19
Study: 7875749

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (preoperative administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Narcotic premedication (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (postoperative administration)
Number of subjects: 0
Study: 3220958

Group type: EXPERIMENTAL
Intervention: Hypnotic 'imaginative involvement'
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Behavioral distraction
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard medical practice (Control)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: All treatment groups (Hypnotic, Distraction, Control)
Number of subjects: 2
Study: 29257939

Group type: EXPERIMENTAL
Intervention: Creative writing instruction combined with reminiscence group intervention over 10 weeks, 1-hour sessions, with various reminiscence themes and writing practices.
Number of subjects: 34
Study: 27494933

Group type: EXPERIMENTAL
Intervention: 3 cm head elevation
Number of subjects: 80

Group type: COMPARATOR
Intervention: 6 cm head elevation
Number of subjects: 80
Study: 26524285

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Present Centered Therapy (PCT)
Number of subjects: 45
Study: 21938543

Group type: EXPERIMENTAL
Intervention: Salsalate (3 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HOMA‐IR
Number of subjects: 60
Study: 20494369

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Number of subjects: 203

Group type: COMPARATOR
Intervention: Surveillance (Control)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Febrile urinary tract infections
Number of subjects: 203
Study: 18301136

Group type: EXPERIMENTAL
Intervention: Early aggressive approach (coronary angiography within 48 hours of admission and, when indicated, coronary revascularization)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Initially conservative approach (optimal medical therapy with coronary angiography in selected cases with refractory ischemia)
Number of subjects: 700
Study: 17133931

Group type: EXPERIMENTAL
Intervention: New fluoride varnish (white varnish)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control fluoride varnish (brown varnish)
Number of subjects: 60
Study: 14606740

Group type: EXPERIMENTAL
Intervention: TENS 1 (4 Hz, 200 micros)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TENS 2 (110 Hz, 200 micros)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 15
Study: 10731276

Group type: EXPERIMENTAL
Intervention: 3 doses of beta-radiation (28, 35, and 42 Gy)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (dummy wire)
Number of subjects: 26
Study: 9365354

Group type: EXPERIMENTAL
Intervention: Isokinetic training program (6 weeks, 3 days/week, 40 minutes/day)
Number of subjects: 15
Study: 1585349

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy combined with hyperthermia
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intraoperative radiation therapy without hyperthermia (control group)
Number of subjects: 69
Study: 2986474

Group type: EXPERIMENTAL
Intervention: magnesium trisilicate mixture (BP) 30 ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg intramuscularly
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg orally on the night prior to, and the morning of, surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg intramuscularly in combination with oral ranitidine 150 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: no medication
Number of subjects: 80
Study: 30727947

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) with 8 extra home sessions over 4 supplementary months
Number of subjects: 240

Group type: COMPARATOR
Intervention: Routine OT delivered as recommended (12 to 15 initial sessions of OT over 3/4 months)
Number of subjects: 240
Study: 29579601

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: LpPLA2 mass/activity
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: high-sensitivity C-reactive protein (hsCRP)
Number of subjects: 668
Study: 27997007

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 25257450

Group type: EXPERIMENTAL
Intervention: Twin-block group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Class II elastic group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22594985

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (ALA, 630-635 nm wavelength)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 85
Study: 20090482

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine 1% with epinephrine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unbuffered lidocaine 1% with epinephrine
Number of subjects: 39
Study: 17396436

Group type: EXPERIMENTAL
Intervention: Behavior modification intervention (half-hour talk on exercise and diet, repeated after 3 months, weekly diaries, weekly phone calls)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (initial instruction only)
Number of subjects: 27
Study: 14557419

Group type: EXPERIMENTAL
Intervention: Combined T(4)/T(3) treatment (liothyronine 10 micro g substituted for 50 micro g of T(4))
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combined T(4)/T(3) treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: T(4) treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of subjects with comparable serum TSH concentrations
Number of subjects: 110
Study: 10848687

Group type: EXPERIMENTAL
Intervention: Nonrefluxing valve irrigation system
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional irrigation system
Number of subjects: 133
Study: 9366660

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 8260338

Group type: EXPERIMENTAL
Intervention: Clinifloat mattress
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Therarest mattress
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 10
Study: 2931515

Group type: EXPERIMENTAL
Intervention: Polydioxanone suture (PDS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ethilon
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nurolon
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prolene
Number of subjects: 100
Study: 30274925

Group type: EXPERIMENTAL
Intervention: Intervention menu with child-friendly labeling
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control menu layout
Number of subjects: 163
Study: 28625890

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 0
Study: 24451659

Group type: EXPERIMENTAL
Intervention: Very preterm participants with no evidence for severe brain injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very preterm participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 0
Study: 23711010

Group type: EXPERIMENTAL
Intervention: Extended release manipulation of the posterior knee clearance
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (cleaned the osteophyte of the posterior condyle only)
Number of subjects: 120
Study: 21220067

Group type: EXPERIMENTAL
Intervention: Emotion-induction condition (distressing)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Emotion-induction condition (neutral)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no DSH)
Number of subjects: 95
Study: 19585911

Group type: EXPERIMENTAL
Intervention: GuttaFlow and a single GP cone
Number of subjects: 3

Group type: COMPARATOR
Intervention: GP using lateral condensation
Number of subjects: 3
Study: 17189672

Group type: EXPERIMENTAL
Intervention: Diclofenac (75mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Parecoxib (40mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14996474

Group type: EXPERIMENTAL
Intervention: Improved glycemic control (n=12)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No improvement in glycemic control (n=7)
Number of subjects: 19
Study: 11025234

Group type: EXPERIMENTAL
Intervention: Sufentanil (10 microg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Clonidine (30 microg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sufentanil (5 microg) + Clonidine (15 microg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 73
Study: 8762789

Group type: EXPERIMENTAL
Intervention: One injection of penicillin G
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Penicillin V tablets for 6 days
Number of subjects: 599

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 599
Study: 1384364

Group type: EXPERIMENTAL
Intervention: Structured, modularized skills training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Supportive group psychotherapy
Number of subjects: 41
Study: 2931988

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/levonorgestrel
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/desogestrel
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 11
Study: 31337647

Group type: EXPERIMENTAL
Intervention: Self-collection-based HPV DNA testing (arm A)
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Visual Inspection with Acetic Acid (VIA) screening (arm B)
Number of subjects: 2356

Group type: EXPERIMENTAL
Intervention: Follow-up for high risk HPV positive women
Number of subjects: 2356
Study: 30336852

Group type: EXPERIMENTAL
Intervention: Intraoperative ketamine (0.5 mg kg-1 or 1.0 mg kg-1)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Combined ketamine (Lo-K plus Hi-K)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 670
Study: 27736142

Group type: EXPERIMENTAL
Intervention: Warning messages during winning slot machine play
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warning messages during losing slot machine play
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no warning messages)
Number of subjects: 0
Study: 23770131

Group type: EXPERIMENTAL
Intervention: Cosmetic camouflage (Microskin™)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63